Page 132 - Aet News Today

Lexicon Pharmaceuticals drug Inpefa is now FDA-approved for heart failure. Inpefa is third in its class, but the biotech says its pill can reach a specific subset of patients, enabling it to stand apart from rival medicines from AstraZeneca and partners Eli Lilly and Boehringer Ingelheim.

Carrum Health's $45 million funding round was led by OMERS Growth Equity and included participation from Revelation Partners, Tiger Global, Wildcat Venture Partners, Cross Creek and SpringRock Ventures. It brings the company’s total financing to about $96 million.

A group of federal agencies recently released an updated set of guidelines to help healthcare organizations protect themselves from ransomware attacks and the data breaches that often follow. The guidance lays out best practices to prevent the six major ways that bad actors gain access to providers’ systems, which include compromised credentials and phishing.

Global funding for digital health companies finally stabilized in Q1 of this year. The sector raised $3.4 billion — this marks the first time the digital health world didn’t experience a quarter-over-quarter funding decline since Q4 of 2021. By holding steady, digital health startups defied the dwindling fundraising totals seen across the broader venture capital landscape, where funding dropped by 13% quarter-over-quarter.

In a series of interviews, two Teladoc Health physicians and a therapist offered a window into a day in the life of delivering virtual care.

A recent webinar sponsored by DexCare explored how the consumerization trend is shifting expectations for health consumers and how companies are enlisting AI tools such as machine learning and Chat GPT to improve the patient experience. Register to access the recording.

AI-generated information can be considered akin to obtaining a second or even third opinion regarding one’s health – it makes up part of what needs to be known, but it’s not the entire story.

Strive Health's $166 million funding round was led by NEA and included participation from CVS Health Ventures, CapitalG, Echo Ventures, Town Hall Ventures, Ascension Ventures and Redpoint. In total, the company has raised more than $400 million.

Frexalimab, a Sanofi drug candidate with roots at Dartmouth’s medical school, has met the main goal of its Phase 2 test. The encouraging data for this program come as different experimental Sanofi MS drug nears its one-year anniversary under FDA clinical hold.

While retailers already have a customer service focus, there is a steep learning curve to healthcare and the nuances of how things operate. It will be critical that these brands do their due diligence and invest in innovations that work to improve the fundamentals of healthcare such as efficient provider credentialing and flexible and sustainable working practices for providers.